May 20, 2015
Theravance Biopharma Presents Additional Positive Phase 2b Study Data on TD-4208 for Treatment of COPD at American Thoracic Society 2015 International Conference
May 18, 2015
Theravance Biopharma Presents Positive Phase 2 Study Data on Velusetrag (TD-5108) for Treatment of Gastroparesis in "Poster of Distinction" at Digestive Disease Week (DDW) 2015
May 7, 2015
Theravance Biopharma, Inc. Reports First Quarter 2015 Financial Results
Medicines that make a difference®
We apply our multivalency expertise to discover, develop and commercialize small molecule medicines for significant unmet medical needs.
We pursue a best-in-class strategy designed to discover superior medicines across multiple therapeutic areas.
In some instances, we partner our programs in order to accelerate timelines and better align resources.
Every day at Theravance Biopharma, we think it through, find a way, and get it done so that together with our partners we can bring patients much needed new medicines.
Theravance Biopharma discovers, develops and brings important medicines to patients by: